Aridis Pharmaceuticals, Inc. ARDS
0.00 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.00145 Day range 0.00145
0.0001 52-week range 0.05
- YTD
- -86.67%
- 1 year
- 0.00%
News
gurufocus.com RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced he
gurufocus.com RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a
gurufocus.com Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi
gurufocus.com RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where
gurufocus.com RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR
globenewswire.com Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart…
globenewswire.com InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced…
globenewswire.com Aridis Provides Corporate Update LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent…
globenewswire.com Aridis Provides Corporate Update LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent…
globenewswire.com InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today…
globenewswire.com MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of…
globenewswire.com Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024 LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective…
globenewswire.com Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health
globenewswire.com Aridis Pharmaceuticals Announces $2 Million Offering Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
globenewswire.com Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301 LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company's proposed…
zacks.com Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301 Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
globenewswire.com Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective…
zacks.com Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
zacks.com Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
pennystocks.com Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer…
benzinga.com Crude Oil Down 2%; Donaldson Shares Drop Following Q3 Results U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 100 points on Wednesday. The Dow traded down 0.34% to 32,929.04 while the NASDAQ fell 0.30% to 12,978.20. The S&P…- benzinga.com Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of…
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 76 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 93 stocks made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's morning session saw 84 companies set new 52-week lows.
- benzinga.com Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 79 stocks hit new 52-week lows.
- benzinga.com Dow Surges Over 100 Points; World Acceptance Shares Spike Higher U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 100 points on Thursday. The Dow traded up 0.35% to 33,863.38 while the NASDAQ rose 1.33% to 11,463.77. The S&P 500…
- benzinga.com US GDP Rises 2.9% In Q4; Crude Oil Up Over 1% U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.27% to 33,834.44 while the…
benzinga.com Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday Gainers
- benzinga.com Why Amazon Shares Traded Lower; Here Are 74 Biggest Movers From Yesterday Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 72.8% to close at $2.16 on Monday as the stock continued to see momentum despite the company last week announcing it is not aware of…
- benzinga.com Why MSP Recovery Is Trading Higher By Over 21%, Here Are 61 Stocks Moving In Monday's Mid-Day Session Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares surged 78% to $2.2399 as the stock continued to see momentum despite the company last week announcing it is not aware of any developments…
- benzinga.com This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal…
- benzinga.com This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11,…
- benzinga.com 76 Biggest Movers From Yesterday Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com 63 Biggest Movers From Yesterday Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
- benzinga.com 44 Stocks Moving In Thursday's Mid-Day Session Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
benzinga.com 55 Biggest Movers From Yesterday Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's morning session, 216 companies made new 52-week lows.
- benzinga.com 64 Biggest Movers From Yesterday Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares climbed 128.8% to settle at $9.06 on Tuesday.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday
- benzinga.com 55 Biggest Movers From Yesterday